EU Clinical Trials Regulation 536/2014 Translation – LIFE SCIENCES & CTR

EU Clinical Trials Regulation (536/2014) and CTIS Launch: Mandatory Lay Summary Translations

/0 Commenti/in , /di

Entering into application on January 31, 2022 alongside the Clinical Trials Information System (CTIS), Regulation (EU) No 536/2014 mandates that clinical trial sponsors publish plain-language Layperson Summaries in the official languages of all participating EU Member States.

Harmonizing Multi-Country Trial Submissions Through CTIS

On January 31, 2022, the European Union Clinical Trials Regulation (Regulation EU No 536/2014) officially entered into application, replacing the legacy Clinical Trials Directive (2001/20/EC). At the heart of the reform is the centralized Clinical Trials Information System (CTIS) managed by the European Medicines Agency (EMA). Under the new regime, pharmaceutical sponsors can submit a single clinical trial application across up to 30 EEA countries simultaneously, subject to strict 12-day Request for Information (RFI) response turnarounds that demand agile, pre-aligned multilingual translation workflows.

EU Clinical Trials Regulation 536/2014 Translation – LIFE SCIENCES & CTR
LIFE SCIENCES & CTR — Professional Localization & Regulatory Quality Assurance (January 11, 2022)

Annex V Plain-Language Summaries and Health Literacy

A landmark transparency requirement under Article 37 and Annex V of the CTR is that within 12 months of a trial’s conclusion (6 months for pediatric trials), sponsors must submit a Summary of Clinical Trial Results written in plain language understandable to laypersons. in accordance with EU Good Lay Summary Practice (GLSP), these summaries must be translated into the official national languages of every EU Member State where the trial was conducted, avoiding medical jargon while preserving scientific accuracy.

Executive Takeaways for Global Enterprises

  • Key Insight: Regulation (EU) No 536/2014 and the EMA CTIS portal go live on January 31, 2022, centralizing EU clinical trial authorizations.
  • Key Insight: Tight 12-day regulatory RFI windows require rapid, ISO 17100-certified medical translation workflows.
  • Key Insight: Annex V mandates plain-language Layperson Summaries translated into all participating Member State languages.

Hai bisogno di traduzioni multilingue certificate, asseverazioni legali o localizzazione conforme agli standard ISO per i tuoi progetti internazionali? Richiedi un preventivo gratuito personalizzato ad Alphatrad e ricevi una risposta dettagliata entro 24 ore.

Editorial & Copyright Attribution Note: This industry analysis has been independently synthesized and adapted by Alphatrad’s editorial team based on verified regulatory documentation and industry research originally published by European Medicines Agency (EMA). For the original publication and primary documentation, please consult:
Source: https://www.ema.europa.eu/en/human-regulatory-overview/research-development/clinical-trials-human-medicines/clinical-trials-regulation

2021 Localization Industry Review – YEAR IN REVIEW

2021 Language Industry Year in Review: Cloud Orchestration, AI Maturity, and Record Demand

/0 Commenti/in , /di

Looking back at 2021, the global translation and localization sector achieved historic expansion—driven by EU regulatory milestones, continuous software localization, neural MT advances, and the enduring value of human subject-matter expertise.

A Landmark Year for Global Content Volume

As 2021 draws to a close, industry benchmarks confirm that the past twelve months have been among the most transformative in the history of professional language services. Enterprise digitalization, cross-border e-commerce, global clinical research, and the implementation of the EU Medical Device Regulation (MDR) generated unprecedented volumes of complex, regulated multilingual content. Far from replacing human linguists, advances in neural machine translation and cloud Translation Management Systems enabled the industry to process exponentially larger content streams.

2021 Localization Industry Review – YEAR IN REVIEW
YEAR IN REVIEW — Professional Localization & Regulatory Quality Assurance (December 21, 2021)

The Convergence of Technology and Certified Human Quality

Throughout 2021, the most successful global organizations embraced a tiered, risk-based approach to localization: deploying automated neural pipelines for high-velocity internal communications while relying on certified human translators, subject-matter revisers, and sworn linguists for legal contracts, medical devices, financial disclosures, and brand-defining marketing campaigns. Entering 2022, data security, terminology precision, and agile turnaround times remain the defining pillars of localization excellence.

Executive Takeaways for Global Enterprises

  • Key Insight: 2021 saw record global demand for specialized translation across life sciences, legal/compliance, software, and digital media.
  • Key Insight: Risk-based localization models successfully pair neural MT speed with ISO-certified human revision where accuracy is mission-critical.
  • Key Insight: Cloud connectivity and API-driven workflows have permanently replaced manual file-based localization management.

Hai bisogno di traduzioni multilingue certificate, asseverazioni legali o localizzazione conforme agli standard ISO per i tuoi progetti internazionali? Richiedi un preventivo gratuito personalizzato ad Alphatrad e ricevi una risposta dettagliata entro 24 ore.

Editorial & Copyright Attribution Note: This industry analysis has been independently synthesized and adapted by Alphatrad’s editorial team based on verified regulatory documentation and industry research originally published by Slator. For the original publication and primary documentation, please consult:
Source: https://slator.com/

EU IVDR 2017/746 Translation Compliance – LIFE SCIENCES & IVDR

Preparing for the 2022 EU In Vitro Diagnostic Regulation (IVDR): Linguistic & Labeling Readiness

/0 Commenti/in , /di

Ahead of the May 2022 application date of Regulation (EU) 2017/746 (IVDR) and the progressive rollout rules announced in late 2021, diagnostic manufacturers must overhaul their multilingual IFU and performance evaluation workflows.

From Self-Certification to Notified Body Scrutiny Under EU IVDR

Under the legacy In Vitro Diagnostic Directive (98/79/EC), roughly 80% of IVD devices—ranging from clinical chemistry analyzers to infectious disease assays—were self-certified by manufacturers without Notified Body intervention. Under Regulation (EU) 2017/746 (IVDR), which applies from May 26, 2022 (with phased transitional periods for existing legacy devices proposed by the European Commission in late 2021), a new risk-based classification system (Classes A, B, C, and D) shifts nearly 80% of IVDs under direct Notified Body oversight. Consequently, translated Instructions for Use (IFUs), labels, and Performance Evaluation Reports form an integral part of the regulated technical documentation.

EU IVDR 2017/746 Translation Compliance – LIFE SCIENCES & IVDR
LIFE SCIENCES & IVDR — Professional Localization & Regulatory Quality Assurance (December 09, 2021)

Self-Testing Diagnostics and Layperson Readability

For self-testing and near-patient diagnostic devices, IVDR mandates that all instructions, warnings, and result interpretations be translated into the official language(s) of the Member State where the test reaches the user, written in clear, unmistakable terminology understandable to laypersons. Partnering with ISO 13485 and ISO 17100 certified language providers ensures terminology consistency across assay packaging, software interfaces, and EUDAMED registrations.

Executive Takeaways for Global Enterprises

  • Key Insight: EU IVDR (Regulation 2017/746) introduces a four-tier risk classification (Class A to Class D), dramatically expanding Notified Body review of translated IFUs.
  • Key Insight: Self-testing diagnostic instructions must be localized for layperson comprehension across all target EU Member State languages.
  • Key Insight: Centralized terminology databases aligned with EDMA and MedDRA standards streamline multi-country regulatory submissions.

Hai bisogno di traduzioni multilingue certificate, asseverazioni legali o localizzazione conforme agli standard ISO per i tuoi progetti internazionali? Richiedi un preventivo gratuito personalizzato ad Alphatrad e ricevi una risposta dettagliata entro 24 ore.

Editorial & Copyright Attribution Note: This industry analysis has been independently synthesized and adapted by Alphatrad’s editorial team based on verified regulatory documentation and industry research originally published by European Commission – Medical Devices & IVDR. For the original publication and primary documentation, please consult:
Source: https://health.ec.europa.eu/medical-devices-sector/new-regulations_en